Publication
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Journal Paper/Review - Jul 1, 2010
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober Jens, Spirig C, Lerch S, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Rochlitz, C
5
0
Ruhstaller, Thomas
83
24
Lerch, S
1
0
Spirig, C
1
0
Huober, Jens
chief physicianBrustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
297
12
Suter, T
2
0
Bühlmann, M
1
0
Fehr, M
8
0
Schonenberger, A
3
0
von Moos, R
25
0
Winterhalder, R
7
0
Rauch, D
7
0
Muller, A
9
0
Mannhart-Harms, M
1
0
Herrmann, R
5
0
Cliffe, B
1
0
Mayer, M
1
0
Zaman, K
5
0
Swiss Group for Clinical Cancer Research (SAKK),
31
0